Michael Barbella, Managing Editor06.24.24
OrganOx Ltd. has officially opened a new 18,000-square-foot global research, development, and production headquarters in Oxford, U.K.
“Our new facility opening is a major milestone, providing OrganOx stakeholders access to world-class facilities and technologies as we work together in ways that were simply not possible previously,” OrganOx CEO Craig Marshall said. “We are proud to be a growing member of the Oxford business and scientific community, and I am greatly looking forward to broader collaborations with commercial and clinical partners.”
Originally spun out from the University of Oxford in 2008, OrganOx developed the world’s first normothermic liver perfusion device, the metra, which debuted in Europe in 2018 and the United States in 2022. metra has gained rapid market adoption since, enabling more organ transplants, eradicating night-time operating, and improving patient outcomes, according to the company.
“We are excited about what the future holds for OrganOx as we continue to push the scientific and clinical boundaries with technology-based solutions designed to improve the lives of patients experiencing acute or chronic organ failure," OrganOx Chief Medical Officer and Co-Founder Prof. Peter Friend, FMedSci, added. "This new facility will support us in that mission for many years to come.”
“Peter and I, surgeon and engineer, could scarcely imagine a day like this when we first began collaborating in an Oxford University laboratory more than 20 years ago,” OrganOx Chief Technology Officer and Co-Founder Prof. Constantin Coussios, OBE FREng FMedSci, stated. “It is a testament to the dedication and efforts of a great many researchers, engineers, transplant surgeons, staff, customers, patients, and business partners, whom we celebrate on this occasion.”
OrganOx is a commercial stage U.K.-based medical device company with a focus on the therapeutic applications of isolated organ perfusion, spun out of the University of Oxford in 2008. Its first product, the OrganOx metra normothermic liver machine perfusion system, has been used to support more than 4,000 liver transplant operations globally, optimizing the use of donated organs by enabling liver quality assessments as well as longer preservation durations. Other therapeutic applications, including in kidney transplantation, are in development.
“Our new facility opening is a major milestone, providing OrganOx stakeholders access to world-class facilities and technologies as we work together in ways that were simply not possible previously,” OrganOx CEO Craig Marshall said. “We are proud to be a growing member of the Oxford business and scientific community, and I am greatly looking forward to broader collaborations with commercial and clinical partners.”
Originally spun out from the University of Oxford in 2008, OrganOx developed the world’s first normothermic liver perfusion device, the metra, which debuted in Europe in 2018 and the United States in 2022. metra has gained rapid market adoption since, enabling more organ transplants, eradicating night-time operating, and improving patient outcomes, according to the company.
“We are excited about what the future holds for OrganOx as we continue to push the scientific and clinical boundaries with technology-based solutions designed to improve the lives of patients experiencing acute or chronic organ failure," OrganOx Chief Medical Officer and Co-Founder Prof. Peter Friend, FMedSci, added. "This new facility will support us in that mission for many years to come.”
“Peter and I, surgeon and engineer, could scarcely imagine a day like this when we first began collaborating in an Oxford University laboratory more than 20 years ago,” OrganOx Chief Technology Officer and Co-Founder Prof. Constantin Coussios, OBE FREng FMedSci, stated. “It is a testament to the dedication and efforts of a great many researchers, engineers, transplant surgeons, staff, customers, patients, and business partners, whom we celebrate on this occasion.”
OrganOx is a commercial stage U.K.-based medical device company with a focus on the therapeutic applications of isolated organ perfusion, spun out of the University of Oxford in 2008. Its first product, the OrganOx metra normothermic liver machine perfusion system, has been used to support more than 4,000 liver transplant operations globally, optimizing the use of donated organs by enabling liver quality assessments as well as longer preservation durations. Other therapeutic applications, including in kidney transplantation, are in development.